ArticleThe Annals of thoracic surgery2026
Pulmonary mucormycosis: outcomes by treatment modality and underlying comorbidity.
Article in The Annals of thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPulmonary mucormycosis is an uncommon highly morbid opportunistic fungal infection that most often affects immunocompromised patients with multiple comorbidities.
methodsWe performed a single-center review of patients diagnosed with pulmonary mucormycosis from 2000-2021 to determine factors associated with selection for surgical intervention, hospital mortality, and overall survival. Factors associated with discharge status were analyzed with logistic regression. Overall survival was compared with log-rank tests.
resultsWe identified 86 patients with pulmonary mucormycosis. The median age was 62 years (interquartile range, 51-67 years); 62 (72.1%) were male. Fifty-four patients (62.8%) had an underlying hematologic malignancy and 22 (25.6%) had a history of solid organ transplantation. Hospital mortality was 46.5%. Patients treated with a combination of surgical resection and antifungal therapy were more likely to discharge alive than those treated with antifungal therapy only (73.2% vs 35.6%, P < .001). Forty-one patients (47.7%) underwent surgical resection. The most common operations were lobectomy (19 patients, 46.3%) and wedge resection (15 patients, 36.6%). Four patients (9.8%) underwent pneumonectomy and 8 patients (19.5%) underwent extrapulmonary resection in addition to lung resection. Median overall survival in patients with hematologic malignancy was lower than those with a solid organ transplant in both the entire cohort (0.20 vs 5.33 years, P = .006) and the surgical cohort (0.57 vs 8.19 years, P = .056).
conclusionsSurgical resection is associated with increased survival to discharge in carefully selected patients with pulmonary mucormycosis, and should be considered in suitable operative candidates even with bilateral and extrapulmonary disease. Underlying hematologic malignancy is associated with poor long-term survival regardless of treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.